Abstract PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamide

Jennifer K. Richer(University of Colorado Anschutz Medical Campus), Dexiang Gao(University of Colorado Cancer Center), Peter Kabos(University of Colorado Anschutz Medical Campus), Tessa McSpadden(University of Colorado Cancer Center), Elena Shagisultanova(University of Colorado Anschutz Medical Campus), Julia Wulfkuhle(University of California, San Francisco), Jill E. Slansky(University of Colorado Anschutz Medical Campus), Andrew Goodspeed(University of Colorado Cancer Center), Jennifer R. Diamond(University of Colorado Anschutz Medical Campus), Alyse Staley(University of Colorado Anschutz Medical Campus), Rosa I. Gallagher(George Mason University), Sharon B. Sams(University of Colorado Denver), Nicole S. Spoelstra(University of Colorado Anschutz Medical Campus), Vida Alami(University of Colorado Cancer Center), Gregory A. Vidal(West Cancer Center), Christian Rickert, Kathryn L. Zolman(University of Colorado Anschutz Medical Campus), Anthony Elias(University of Colorado Cancer Center), Emanuel Petricoin(George Mason University), Virginia F. Borges(University of Colorado Anschutz Medical Campus), Kimberly R. Jordon, Monica Fornier(Cornell University)
Clinical Cancer Research
June 13, 2025
Cited by 0


Related Papers